论文部分内容阅读
目的:探讨塞来昔布胶囊联合盐酸坦索罗辛治疗前列腺增生伴下尿路症状的临床效果。方法:抽取2020年1月至2020年12月濮阳市中医医院收治的前列腺增生伴下尿路症状患者204例，按随机数字表法分为观察组(102例)与对照组(102例)。对照组采用盐酸坦索罗辛治疗，观察组在对照组基础上采用塞来昔布胶囊。比较两组治疗效果，国际前列腺症状量表(IPSS)评分，平均尿流率(AFR)，前列腺体积，残余尿量，膀胱功能包括最大膀胱压容量(MCC)及膀胱出口梗阻指数(BOOI)，尿动力学评估包括初始尿意容量(FDV)、膀胱过度活动症状评分(OABSS)及不良反应发生率。结果:观察组总有效率(90.20%)高于对照组(80.39%)(n P<0.05)；治疗后，观察组IPSS评分为(7.87±0.25)分，低于对照组的(6.76±0.26)分，AFR为(8.46±0.43)ml/s，快于对照组的(6.76±0.26)ml/s(n P0.05)，观察组残余尿量为(23.67±1.25)ml，少于对照组的(43.26±2.54)ml(n P<0.05)；治疗后，观察组MCC及BOOI为(271.54±13.24)ml、50.32±3.26，高于对照组的(235.47±10.59)ml、43.25±2.59(n P<0.05)；治疗后，观察组FDV为(160.54±5.32)ml，大于对照组的(139.87±4.65)ml，OABSS评分为(4.21±0.23)分，高于对照组的(5.18±0.35)分(n P0.05)。n 结论:塞来昔布胶囊联合盐酸坦索罗辛治疗前列腺增生伴下尿路症状患者有利于提高治疗效果，改善膀胱功能，增强患者尿动力学，且具备用药安全性。“,”Objective:To investigate the effect of celecoxib capsule combined with tamsulosin hydrochloride in the treatment of benign prostatic hyperplasia complicated by lower urinary tract symptoms.Methods:A total of 204 patients with benign prostatic hyperplasia complicated by lower urinary tract symptoms treated in Puyang Hospital of Traditional Chinese Medicine from January 2020 to December 2020 were selected, they were divided into observation group(102 cases) and control group (102 cases) according to random number table method. The control group was treated with tamsulosin hydrochloride, and the observation group was treated with celecoxib capsule based on the basis of control group. The effects, the International Prostate Symptom Scale (IPSS) score, average urinary flow rate (AFR), prostate volume, residual urine volume, bladder function including maximum cystometric capacity (MCC) and bladder outlet obstruction index (BOOI), urodynamic evaluation including first desire to void (FDV), Overactive Bladder Symptom Score(OABSS) and the incidence of adverse reactions of the two groups were compared.Results:The total effective rate of the observation groupwas 90.20%(92/102), which was higher than 80.39% (82/102) of the control group (n P<0.05). After treatment, the IPSS score of the observation groupwas (7.87±0.25)points, which was lower than (6.76±0.26) points of the control group, and the AFR was (8.46±0.43) ml/s, which was faster than (6.76±0.26) ml / s of the control group (n P0.05), and the residual urine volume in the observation groupwas (23.67±1.25) ml, which was lower than (43.26±2.54) ml in the control group (n P<0.05). After treatment, MCC and BOOI in the observation groupwere (271.54±13.24) ml and 50.32±3.26, which were higher than (235.47±10.59) ml and 43.25±2.59 in the control group (n P<0.05). After treatment, the FDV of the observation groupwas (160.54±5.32) ml, which was higher than that of the control group (139.87±4.65) ml, and the oabss score was (4.21±0.23) points, which was higher than that of the control group (5.18±0.35),n P<0.05. The incidence of adverse reactions in the observation group was 9.80% (10/102), and there was no significant difference compared with 7.84% (8 /102) in the control group.n Conclusions:Celecoxib capsule combined with tamsulosin hydrochloride in the treatment of benign prostatic hyperplasia with lower urinary tract symptoms is beneficial to improve the efficacy, improve bladder function, enhance urodynamics of patients, with drug safety.